[HTML][HTML] Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter …

D Yin, W Chayoua, H Kelchtermans… - Journal of Thrombosis …, 2020 - Elsevier
Background Classification of the antiphospholipid syndrome (APS) relies predominantly on
detecting antiphospholipid antibodies (aPLs). Antibodies against a domain I (DI) epitope of …

Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome

L Meneghel, A Ruffatti, S Gavasso, M Tonello… - Clinica Chimica …, 2015 - Elsevier
Abstract Background IgG anti-Domain I (anti-DI) β2 Glycoprotein I (β2GPI) antibodies are
associated to thrombotic risk in antiphospholipid syndrome (APS), but their detection is …

Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome

T Iwaniec, MP Kaczor, M Celińska-Löwenhoff… - Thrombosis …, 2017 - Elsevier
Background Antiphospholipid syndrome (APS) is characterized by the presence of
circulating antiphospholipid antibodies (aPL) in patients with thrombosis and/or pregnancy …

Detection of anti-cardiolipin and anti-β2glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms

W Chayoua, H Kelchtermans, GW Moore… - Thrombosis and …, 2019 - thieme-connect.com
Background The anti-phospholipid syndrome (APS) is characterized by thrombosis and/or
pregnancy morbidity with persistent presence of anti-phospholipid antibodies (aPL) …

[HTML][HTML] The (non‐) sense of detecting anti‐cardiolipin and anti‐β2glycoprotein I IgM antibodies in the antiphospholipid syndrome

W Chayoua, H Kelchtermans, JC Gris… - Journal of Thrombosis …, 2020 - Elsevier
Background The antiphospholipid syndrome (APS) is characterized by thrombosis and/or
pregnancy morbidity with the persistent presence of lupus anticoagulant (LAC), anti …

Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome

R Mondejar, C González-Rodríguez, FJTS De Miera… - Clinica Chimica …, 2014 - Elsevier
Background Antiphospholipid syndrome (APS) is characterized by the presence circulating
antiphospholipid (aPL) antibodies in patients with thrombosis or pregnancy morbidity …

New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies

CB Chighizola, M Gerosa, PL Meroni - Current rheumatology reports, 2014 - Springer
Abstract Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …

Laboratory Evaluation of Antiphospholipid Syndrome: Is There a Role for Specific Noncriteria Antiphospholipid Antibody Tests?

N Heikal, TB Martins, SK White, R Willis… - American Journal of …, 2019 - academic.oup.com
Objectives Anti-β2 glycoprotein I domain I (anti-domain I) and anti-phosphatidylserine/
prothrombin (aPS/PT) antibodies are present in patients with antiphospholipid syndrome …

The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: a systematic review

H Meijide, S Sciascia, G Sanna, MA Khamashta… - Autoimmunity …, 2013 - Elsevier
The antiphospholipid syndrome (APS) is diagnosed in patients with thromboembolic events
and/or pregnancy loss in the presence of persistent laboratory evidence for antiphospholipid …

How to diagnose and manage antiphospholipid syndrome

A Hubben, KR McCrae - Hematology, 2023 - ashpublications.org
Antiphospholipid antibodies (aPL) are autoimmune antibodies directed toward
phospholipids or phospholipid-protein complexes, particularly those containing β2 …